These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6100173)

  • 21. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.
    Girard D; Finegan SM; Dunne MW; Lame ME
    J Antimicrob Chemother; 2005 Aug; 56(2):365-71. PubMed ID: 16002421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of cefotaxime, ceftizoxime, cefmenoxime, and latamoxef in comparison with other beta-lactam antibiotics against recent clinical isolates of Haemophilus influenzae and Haemophilus parainfluenzae.
    Kawakami Y; Okimura Y; Horiuchi N; Kanai M
    Microbiol Immunol; 1982; 26(7):617-21. PubMed ID: 6290854
    [No Abstract]   [Full Text] [Related]  

  • 23. [Comparison of antimicrobial activity and stability to beta-lactamases of cefoperazone, cefotaxime, lamoxactam and ceftriaxon].
    Baumgärtner M; Grehn M; Wundt W
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jun; 252(2):208-21. PubMed ID: 6289564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin.
    Beskid G; Christenson JG; Cleeland R; DeLorenzo W; Trown PW
    Antimicrob Agents Chemother; 1981 Aug; 20(2):159-67. PubMed ID: 6269487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of ceftriaxone (R013-9904) in the treatment of septicemia caused by gram-negative bacilli].
    Naessens A; Pierard D; Roels P; Lauwers S
    Pathol Biol (Paris); 1983 May; 31(5):362-5. PubMed ID: 6312398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review.
    Bijie H; Kulpradist S; Manalaysay M; Soebandrio A
    J Chemother; 2005 Feb; 17(1):3-24. PubMed ID: 15828439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies.
    Gums JG; Boatwright DW; Camblin M; Halstead DC; Jones ME; Sanderson R
    Ann Pharmacother; 2008 Jan; 42(1):71-9. PubMed ID: 18094350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftriaxone: increasing the half-life and activity of third generation cephalosporins.
    Steele RW
    Pediatr Infect Dis; 1985; 4(2):188-91. PubMed ID: 3885182
    [No Abstract]   [Full Text] [Related]  

  • 30. Ceftriaxone: a long-acting cephalosporin.
    Am J Med; 1984 Oct; 77(4C):1-118. PubMed ID: 6093510
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative pharmacokinetic evaluation of ceftriaxone and cefotaxime in coincidence for short-term antimicrobial prophylaxis in surgery.
    Periti P; Mazzei T; Costantini A; Rizzo M; Gasparri F; Scarselli G; Alaimo E; Finistorchi O; Nicoletti P
    Chemioterapia; 1984 Oct; 3(5):305-9. PubMed ID: 6099758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy of cefotiam, cefmenoxime, and ceftriaxone in experimental endocarditis and correlation with pharmacokinetics and in vitro efficacy.
    Pangon B; Joly V; Vallois JM; Abel L; Buré A; Brion N; Contrepois A; Carbon C
    Antimicrob Agents Chemother; 1987 Apr; 31(4):518-22. PubMed ID: 3300530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis.
    Del Rio M; McCracken GH; Nelson JD; Chrane D; Shelton S
    Antimicrob Agents Chemother; 1982 Oct; 22(4):622-7. PubMed ID: 6295262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of ceftriaxone and its relation to concentrations in extravascular compartments. Comparison with cefotaxime.
    Regamey C
    Chemotherapy; 1985; 31(2):85-94. PubMed ID: 3987394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftriaxone in patients with streptococcal endocarditis.
    Mittermayer HW
    Am J Surg; 1984 Oct; 148(4A):41. PubMed ID: 6091480
    [No Abstract]   [Full Text] [Related]  

  • 36. [Influence of protein binding on the antibacterial effects of 2 cephalosporins].
    Meinardi G; Grasso S; de Carneri I
    G Ital Chemioter; 1985; 32(2):343-6. PubMed ID: 3869113
    [No Abstract]   [Full Text] [Related]  

  • 37. Abnormal laboratory test values during ceftriaxone therapy.
    Oakes M; MacDonald H; Wilson D
    Am J Med; 1984 Oct; 77(4C):89-96. PubMed ID: 6093527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of acute respiratory infections in childhood with a new cephalosporin, ceftriaxone].
    Berni Canani M; Leone L; Della Rotonda G; Palazzi A
    Pediatr Med Chir; 1984; 6(2):277-80. PubMed ID: 6099551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftriaxone therapy of group B streptococcal bacteraemia and meningitis in infant rats.
    Delaplane D; Yogev R; Shulman ST
    J Antimicrob Chemother; 1983 Jan; 11(1):69-73. PubMed ID: 6298176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
    Brogden RN; Spencer CM
    Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.